Trials / Completed
CompletedNCT00674453
The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation
The Effect Of Lasofoxifene On Local Mediators Of Bone Resorption In The Prevention Of Postmenopausal Osteoporosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Ligand Pharmaceuticals · Industry
- Sex
- Female
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to demonstrate the effects that lasofoxifene has on serum markers of bone metabolism.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lasofoxifene | Oral tablet, 0.25 mg, daily, 2 years |
| OTHER | Placebo | Matching placebo tablet given once daily for 2 years |
Timeline
- Start date
- 2004-09-01
- Completion
- 2007-09-01
- First posted
- 2008-05-07
- Last updated
- 2011-08-10
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00674453. Inclusion in this directory is not an endorsement.